[Oseltamivir in pregnancy, lactation and neonatal period--comparison of international recommendations].
BACKGROUND
In the current influenza A (H1N1) pandemia, data on neonatal and maternal Oseltamivir chemoprophylaxis and treatment are limited. Recommendations of national and international health authorities do not compensate for a lack of controlled studies on pharmacokinetics and safety. However, the level of consent may contribute to individual clinical decisions.


METHODS
We have reviewed online recommendations by health authorities in the context of the current literature.


RESULTS
Given the limited database, there is a high level of consent among recommendations issued by health authorities regarding treatment with Oseltamivir and breast-feeding.


CONCLUSIONS
The majority of recommendations do not regard treatment with Oseltamivir as a contraindication to breast-feeding. Antiviral chemoprophylaxis of influenza A (H1N1) infection in preterm infants is not recommended due to the lack of data on its pharmacokinetics and safety.


CONCLUSIONS
Variable recommendations have been issued regarding the choice of neuraminidase inhibitors in pregnancy. Additional information on the pharmacokinetics and safety of neuraminidase inhibitors for breast-feeding mothers and neonates is essential in order to address potential future pandemics.
Dembinski
J
J
Klinik für Kinder-und Jugendmedizin, Klinikum Itzehoe.
D005260:Female; D006801:Humans; D007231:Infant, Newborn; D053118:Influenza A Virus, H1N1 Subtype; D007251:Influenza, Human / Q000517:prevention & control*; D007774:Lactation / Q000187:drug effects*; D053139:Oseltamivir / Q000008:administration & dosage* / Q000009:adverse effects*; D011181:Postnatal Care / Q000592:standards*; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000517:prevention & control*
D053139:Oseltamivir